Electronic Submissions of De Novo Applications Required in 2025
Starting October 2025, the U.S. Food and Drug Administration (FDA) will require all De Novo classification requests to be submitted electronically, via the electronic Submission Resource and Resource (eSTAR) template, marking a significant shift in regulatory submission processes for medical devices. This transition aims to streamline the approval process and enhance the efficiency of device […]
TGA Seeks to Align Essential Principles with EU Regulations
In a bid to harmonize regulatory practices and streamline the approval process for medical technologies, the Therapeutic Goods Administration (TGA) has initiated a consultation to align Australian Essential Principles with European Union (EU) Regulations’ General Safety and Performance Requirements (GSPR). This move marks a significant step toward improving market access, ensuring safety, and fostering innovation […]
EMA Launches a Pilot Program on Orphan Medical Devices
In a significant move to address a critical gap in the healthcare industry, a new pilot program has been launched to support orphan medical devices. On August 2, 2024, the European Medicines Agency (EMA) announced that its effort, as mandated under Regulation (EU) 2022/123 (Regulation – 2022/123 – EN – EUR-Lex (europa.eu)), aims to provide […]
Device Classification
Background and Problem A US based manufacturer of sample preparations reagents and instruments needed an outside opinion of their regulatory compliance regarding labeling certain devices as “Research Use Only (RUO)” in the United States and the European Union. The manufacturer also wanted assistance to develop an approach on how best to register and list a […]
TGA Considering Regulatory Governance of Integrating Assistive Technologies
The Therapeutic Goods Administration (TGA) is reaching out to stakeholders for feedback on a significant initiative that could reshape the landscape of medical technology in Australia. This initiative focuses on incorporating assistive technologies into the existing medical technology (MedTech) framework by treating them as consumer goods, rather than therapeutic goods. Assistive technologies are devices or […]
Guidance for Essential Drug Delivery Outputs for Devices
The draft guidance document titled “Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products” released by the FDA in June 2024 provides industry stakeholders with key recommendations on essential drug delivery outputs (EDDOs) for drug delivery devices and combination products. EDDOs are critical to the design process and essential in ensuring […]
Regulatory Strategy & 510(k) Submission Support
CHALLENGE: A new US based division manufacturer of a Chinese dental implant, wanted to grow their business by bringing their product, material used in the construction of dental implants, to the US market. With no prior experience in US medical device regulations, they needed assistance determining the best regulatory path and guidance to navigate the […]
CDER Emerging Drug Safety Technology Program
The Emerging Drug Safety Technology Program (EDSTP) is dedicated to the integration of artificial intelligence (AI) and emerging technologies within pharmacovigilance (PV) to advance drug safety and lifecycle management. This program fosters communication with the pharmaceutical industry to enhance the FDA’s understanding of AI-enabled tools and other technologies in PV, aiming to assess their performance, […]
The EU AI ACT: Implications for the Medical Device Industry
The European Union’s recent strides in regulating artificial intelligence (AI) have garnered significant attention, particularly with the introduction of the EU AI Act. This landmark legislation aims to establish a comprehensive regulatory framework for AI systems across various sectors. Among those affected, the medical device industry finds itself at a crucial crossroads, as the implementation […]
ACLA’s Bold Move: Challenging FDA’s Final Rule on LDTs
In a groundbreaking legal maneuver, the American Clinical Laboratory Association (ACLA) has filed the first lawsuit in an attempt to block the implementation of the Food and Drug Administration’s (FDA) Final Rule on Laboratory Developed Tests (LDTs). The contentious Final Rule, which aims to regulate LDTs, has sparked heated debates within the healthcare and regulatory […]
